The medicine is commonly used as an add-on therapy for the symptomatic treatment of adult patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies. This therapeutic use is in line with regulatory guidance for the management of chest discomfort due to chronic ischemic heart disease.

Tricardia is considered relevant for easing symptoms associated with stable angina pectoris and myocardial ischemia, such as recurrent chest tightness or functional limitation during activity. It is generally applied in conditions characterized by episodic or fluctuating manifestations of pain and supports the patient by providing relief that contributes to easing the overall symptom load.

Primary Symptomatic Benefit

It is relevant for easing symptoms that interfere with daily functioning by assisting with maintaining functional stability. The use of Tricardia is also relevant for patients whose underlying conditions, such as existing low blood pressure or heart rate, mean that alternative options may be preferred in their care.

“The medication supports the patient during difficult episodes by easing distress and may assist with managing the frequency of angina attacks.”

---

Quick Fact: Relief for Chest Discomfort

The therapeutic role of the medicine is to help with the reduction in the frequency of angina attacks and to contribute to an improved capacity for physical activity, which supports patients in maintaining comfort during symptomatic periods.

Who Can and Cannot Use Tricardia?

The population eligibility for Tricardia (Trimetazidine) is strictly defined by regulatory documents, focusing on absolute exclusions and populations requiring caution.

Contraindicated Populations

Tricardia must not be used by patients who have specific health conditions, classified as absolute contraindications in official labeling:

• Patients with Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, or other related movement disorders.
• Individuals with severe renal impairment (creatinine clearance less than 30 mL/min).
• Patients with known hypersensitivity to the active substance.

Age and Special Population Restrictions

Use is restricted only to adults (18 years and older). Safety and efficacy have not been established in children and adolescents, and therefore, use is not recommended in patients below 18 years of age.

Caution is advised for elderly patients over 75 years and those with moderate renal impairment (creatinine clearance 30 –60 mL/min), often requiring conditional use. Furthermore, the medicine is not recommended for women who are breastfeeding, and it is preferable to avoid use during pregnancy.

Interactions with other medicines and products

The interaction profile for Tricardia (Trimetazidine), based on official regulatory documents, is predominantly characterized by the absence of formal drug-drug interactions.

Documented Interaction Profile

Absence of Drug-Drug Interactions: The official prescribing information explicitly states that no clinically significant drug-drug interactions have been identified. Studies confirm the drug is not documented as having a significant effect on major metabolic pathways; it is neither an inducer nor an inhibitor of common drug-metabolizing enzymes and does not significantly interact with the P-glycoprotein transporter system. Consequently, no mandatory timing separation rules are required for co-administration with other medicines.

Non-Interactions with Food and Supplements: Regulatory data confirms that no interactions with foodstuffs have been found, as the drug's absorption and clearance characteristics are not influenced by meals. Furthermore, no formal interactions with alcohol, herbal products, or supplements are documented in the official labeling.

Population-Specific and Procedural Constraints: The primary regulatory constraints relate to patient clearance capacity:

• The medicine is contraindicated for use in patients with severe renal impairment (creatinine clearance less than 30 mL/min) due to the expected risk of drug accumulation and significantly increased systemic exposure.
• Increased systemic exposure is also anticipated in the elderly and in those with moderate renal impairment.
• The active substance may result in a positive reaction in regulatory anti-doping tests.

How Tricardia Works: Mechanism of Action

Tricardia's active ingredient, Trimetazidine, functions as a specialized metabolic modulator, modulating myocardial energy substrate preference, which contrasts with agents that alter systemic hemodynamics. The drug's primary action is the selective, partial inhibition of the mitochondrial enzyme long-chain 3-ketoacyl-CoA thiolase ( LC 3-KAT). This direct interaction reduces the rate of fatty acid oxidation (FAO), leading to a compensatory shift toward glucose oxidation, a pathway that yields a higher ATP per unit of oxygen consumed. This metabolic shift initiates a cascade resulting in cellular stabilization: it limits H^+ buildup, mitigating intracellular acidosis, which, in turn, indirectly prevents the excessive activation of ion exchange systems. This mechanism restricts calcium overload inside the myocardial cells, maintaining cellular structure and function under conditions of constrained oxygen supply.

How to Use Tricardia

This section outlines the standard administration guidelines for Trimetazidine (Tricardia) as an adjunctive treatment for stable angina, based strictly on official prescribing information.

---

Official Dosing and Administration

Trimetazidine is approved for oral administration and is typically available as a 35 mg modified-release (MR) tablet or a 20 mg immediate-release (IR) tablet. The specific dosing regimen depends on the formulation used:

Formulation	Standard Adult Dose	Daily Frequency	Administration Context
35 mg MR Tablet	One 35 mg tablet	Twice daily (morning and evening)	Must be taken during meals
20 mg IR Tablet	One 20 mg tablet	Three times daily	Must be taken during meals

These regimens establish the maximum recommended daily dose for routine use.

---

Procedural Instructions and Patient Groups

For the modified-release formulation, the tablet must be swallowed whole and should not be crushed, broken, or chewed, as this compromises the extended-release properties.

In specific patient populations, a dosage adjustment is required. Patients with moderate renal impairment (Creatinine Clearance 30-60 ml/min) require a reduced dose of one 35 mg MR tablet once daily (total 35 mg/day) or one 20 mg IR tablet twice daily. Use in patients under 18 years is not recommended.

The overall course of treatment should be formally assessed after three months of use; if no therapeutic response is observed, discontinuation is generally specified in the official protocol. If a dose is missed, treatment should be resumed normally with the next scheduled dose, and the patient must not take a double dose to compensate.

Research Evidence for Stable Angina Pectoris

---

This section summarizes research studies, primarily from Randomized Controlled Trials (RCTs) and meta-analyses, which evaluated the use of Tricardia as an add-on treatment for Stable Angina Pectoris. Studies focused on adults whose symptoms persisted despite standard therapy. Researchers compared groups receiving Tricardia with placebo to study changes in outcomes related to physical discomfort. Research groups examined the weekly frequency of angina episodes and monitored the consumption of short-acting nitrate rescue medication. Trials also explored daily functioning by measuring changes in exercise duration and the time until symptoms appeared during exertion. Findings describe patterns where trials reported measurements of lower weekly angina attacks and monitored that the time to onset of symptoms was extended in the Tricardia groups compared to control groups.

---

Long-term Follow-up and Evidence Gaps

The majority of core efficacy trials exploring short-term symptom changes had follow-up durations that were limited, often lasting only 2 to 3 months. Researchers have tracked extended-duration data, sometimes up to 4 years, monitoring hard outcomes such as cardiac mortality and the occurrence of other serious cardiovascular events. While these extended studies describe patterns related to the duration of observed symptom changes, long-term effects are not fully established regarding the medicine's impact on major clinical events. Data are still emerging regarding the role of the medicine in overall cardiac prognosis.

---

Evidence Quality and Uncertainty

The research base includes studies for specific subgroups, such as patient groups with co-existing Type 2 Diabetes Mellitus. However, data for certain groups remain insufficient, and the sample sizes were modest in many trials focusing on specific patient types. Research describes patterns where outcomes related to physical discomfort were observed in some studies, but findings related to functional measures were mixed. Overall, certainty remains low regarding its full role relative to other standard therapies, and research is ongoing to provide further clarity on its application.

Key Studies & References Trimetazidine for the treatment of angina: a review of the evidence

Common questions about Tricardia (FAQ)

---

Q: How long do the effects of one dose of Tricardia last?

Regulatory data indicates that the amount of time the drug remains in the body varies based on patient age and the formulation used. The elimination half-life is around 7 hours in young adults but extends to approximately 12 hours in older patients. The modified-release tablet is specifically engineered to maintain effective plasma concentrations for about 11 hours.

---

Q: Is Tricardia a long-term treatment or is it usually for a short time?

Official prescribing information states that the patient's need for continued treatment should be assessed after the first three months of use. If regulatory assessments find no therapeutic response after this period, official guidance generally specifies that the medicine may be discontinued.

---

Q: Why is Tricardia sometimes compared to other anti-angina medicines?

Tricardia is classified as a Metabolic Agent (a medicine that shifts heart cell energy use), rather than a hemodynamic agent (one that alters blood pressure or heart rate). Official information indicates that this unique mechanism differentiates its therapeutic approach from other medicines, which may be why its overall role is often discussed in relation to other standard anti-anginal treatments.

---

Q: Are there known food or drink restrictions when taking Tricardia?

Regulatory documents indicate that the drug's absorption is not influenced by food, so there is no formal food interaction. However, the official administration instructions for the tablets specify that the medicine should be taken during meals as part of the standard regimen.

---

Q: Is Tricardia safe to use during pregnancy, according to official classification?

Official documents state that there are currently no adequate data available regarding the use of this medicine in pregnant women. As a precautionary measure and due to the lack of evidence, official guidance indicates that its use is preferable to be avoided during pregnancy.

---

Q: Is Tricardia available as a generic medicine?

The active ingredient in this medicine is Trimetazidine. This substance is authorized and available worldwide under several different brand names, and generic equivalent formulations are also commercially available in many countries.

---

Q: What is the purpose of the different strengths of Tricardia tablets?

The different strengths correspond to different release formats. The lower strength is often an immediate-release (IR) tablet taken more frequently per day. The higher strength is usually a modified-release (MR) tablet designed to be taken less often while maintaining steady blood concentrations over a longer period.

---

Q: Does the time of day matter when taking Tricardia?

For the modified-release formulation, the official recommended regimen specifies taking the tablet twice daily: once in the morning and once in the evening. This specific timing helps ensure a consistent level of the medicine is maintained in the body, as required by the standard administration instructions.

---

Q: Have studies been done on Tricardia's long-term safety?

Yes, studies with extended follow-up periods, tracking patients for up to nearly four years, have been conducted. Regulatory assessments based on this data described patterns of use in these long-term study populations. However, its impact on preventing major long-term clinical events was not established in these trials.

---

Q: Can Tricardia cause issues with sleep?

According to official regulatory documents, drowsiness is listed as a Common side effect. In addition, the regulatory label notes sleep disorders, such as difficulty in sleeping, among the adverse reactions with an unconfirmed frequency.

---

Q: Why is it important to tell the doctor about all other medicines when starting Tricardia?

While regulatory documents state that no clinically significant drug-drug interactions have been identified, disclosing all medications is standard medical practice. This allows doctors to check for potential drug-condition interactions—such as pre-existing severe kidney disease—and to screen for any hidden ingredients that might increase the risk of known side effects.

---

Q: What do official sources say about taking Tricardia with other heart medicines?

Official therapeutic indications state that the drug is used as an add-on therapy for the symptomatic treatment of stable angina in patients already using standard first-line antianginal medicines. Regulatory information confirms there are no clinically significant interactions with these other heart drugs.

---

Q: Has Tricardia been studied in older adults?

Yes, the medicine has been studied in older adults. Regulatory documents note that in patients over 65 years, the time it takes for the body to eliminate the drug (half-life) is extended. This pharmacokinetic difference, linked to age-related changes in kidney function, is why official guidance specifies that caution and potential dose adjustment may be required in this population.

---

Q: Are there any long-term effects of Tricardia use on the body?

Studies with long-term follow-up, some lasting several years, have investigated the medicine's profile. Regulatory assessments indicate that while the medicine has generally been found to be used safely in these long-term studies, its impact on major clinical events (such as cardiovascular mortality) has not been established.

---

Q: How quickly should I expect Tricardia to start working?

Pharmacokinetic data indicates that the immediate-release formulation reaches its highest concentration in the bloodstream within approximately two hours. However, the medicine is explicitly not intended for the initial treatment of acute angina attacks, and official prescribing information specifies that the clinical response is formally assessed after three months of use.

---

Q: Is it safe to use Tricardia if I have liver disease?

Official prescribing information indicates that there is a lack of specific data available regarding how the drug acts in patients with hepatic (liver) impairment. Regulatory documents state that no pharmacokinetic data are available on the use of this medicine in patients with pre-existing liver disease.

---

Q: Is Tricardia used to prevent heart attacks?

Official warnings explicitly state that the medicine is not a treatment for myocardial infarction (heart attack) or unstable angina. Its sole indicated use, according to regulatory documents, is for the symptomatic treatment of stable angina pectoris.

---

Q: Is Tricardia widely used in other countries?

The active ingredient, Trimetazidine, is authorized and commercially available in many countries across Europe, Asia, and other regions. It is sold globally under various brand names, including Vastarel and Preductal.

---

Q: How long does it take for Tricardia to clear out of the system?

Official pharmacokinetic information states that the medicine is eliminated primarily through the urine, with more than 80% of the medicine cleared from the body within 48 hours. The elimination half-life in young adults is approximately 6 to 7 hours.

---

Q: Is the brand name Tricardia the only version available?

No, the active ingredient, Trimetazidine, is commercially available under several different brand names worldwide, including Vastarel and Preductal, depending on the country.

---

Q: Does Tricardia need a special prescription?

The medicine is classified as a prescription-only product. According to regulatory guidance, it can only be legally obtained with a valid prescription from a doctor.

How to Store and Dispose of Tricardia (Trimetazidine Dihydrochloride)

The official labeling defines specific requirements for storing and disposing of Trimetazidine dihydrochloride tablets.

---

Storage and Handling

• Temperature: Store the product at temperatures not exceeding 30 C.
• Protection: The tablets must be kept in their original blister pack and outer box until the expiry date.
• Safety: The medicine must be kept out of the sight and reach of children.

---

Disposal Instructions

• Environment: Do not dispose of unused or expired tablets via wastewater or household waste.
• Procedure: Unused product should be discarded in accordance with local requirements, typically by returning it to a pharmacist for proper disposal.